News from rigel pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 16, 2014, 08:35 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Initiates Phase 3 Studies of Fostamatinib in ITP

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib,...

May 29, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel to Present at Jefferies 2014 Global Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to...

May 07, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces First Quarter 2014 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2014. For the first...

Apr 30, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Webcast of Investor Day on May 6, 2014

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will host an Investor Day on Tuesday, May 6, 2014 from 9:30 a.m. to 12:00...

Mar 06, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Publication of R118 AMPK Activator Research

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the American Journal of Physiology has published recent research results with its...

Mar 04, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Fourth Quarter and Year End 2013 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2013. For the...

Feb 27, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Participation at Two Investor Conferences

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that company management will present at two upcoming investor conferences. Details of...

Feb 06, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Participation at Two Investor Conferences

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is...

Jan 10, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present...

Dec 05, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel to Present at Oppenheimer Healthcare Conference

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul R. Rodriguez, the company's president and chief operations officer, is...

Nov 05, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Third Quarter 2013 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30,...

Oct 24, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Provides Pipeline Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological...

Sep 06, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel to Present at Stifel Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to...

Sep 05, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel To Focus On ITP, DLE And Dry Eye

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced its plans to focus the Company's resources on the completion of three lead...

Aug 26, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel's R343 Did Not Meet Primary Endpoint in Asthma Study

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R343, an inhaled SYK inhibitor being evaluated as a potential therapeutic for...

Aug 06, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Second Quarter 2013 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30,...

Jun 04, 2013, 02:00 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Will Resume Responsibility for Fostamatinib Program

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and AstraZeneca AB (AZ) today announced the topline results from OSKIRA-2 and OSKIRA-3, the...

May 22, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the clinical advancement of three programs in development. The first program is a...

May 07, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces First Quarter 2013 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2013. For the first quarter...

Apr 05, 2013, 02:01 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis

 AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge